Clinical Trials Logo

Retinal Detachment clinical trials

View clinical trials related to Retinal Detachment.

Filter by:

NCT ID: NCT06324305 Not yet recruiting - Clinical trials for Rhegmatogenous Retinal Detachment

Comparative Study Between Three Different Techniques in Drainage of SRF During PPV in RRD

Start date: April 1, 2024
Phase: N/A
Study type: Interventional

The study will investigate and compare the three techniques in drainage of subretinal fluid in patients with macula off RRD: namely using the original break, performing a posterior drainage retinotomy and using PFC with drainage through the original break or peripheral retinotomy regarding the presence of persistent sub-retnal fluid and related intra or postoperative complications

NCT ID: NCT06294847 Not yet recruiting - Retinal Detachment Clinical Trials

Ursodeoxycholic Acid (UDCA) as a Neuroprotective Adjuvant Treatment to Rhegmatogenous Retinal Detachment Surgery

UDCA
Start date: April 2024
Phase: Phase 3
Study type: Interventional

This study is indicated for patients with extended rhegmatogenous retinal detachment (RRD) (≥ 2 quadrants) with macula OFF lasting 7 days or less, pseudophakic or aphakic, and scheduled to undergo surgical intervention with vitrectomy and gas tamponade in one of the ophthalmology departments participating in the study. The main objective is to assess the effectiveness of UDCA in visual acuity recovery at 3 months (i.e., the difference between preoperative visual acuity and visual acuity 3 months after surgery) in pseudophakic or aphakic patients who have undergone successful surgical intervention (reattachment of the retina) through vitrectomy and gas tamponade following rhegmatogenous retinal detachment (RRD). 120 patients will be enrolled and randomized in two groups: - the experimental arm "UDCA Group," with oral administration of ursodeoxycholic acid (Ursolvan®) - the control group "Placebo Group," with oral administration of the placebo.

NCT ID: NCT06292572 Not yet recruiting - Retinal Detachment Clinical Trials

Clinical Characteristics and Surgical Outcomes of the Fellow Eye in Bilateral Retinal Detachments

Start date: March 1, 2024
Phase:
Study type: Observational

To assess the clinical features and the surgical outcomes of RD repair surgery of the fellow eye in bilateral retinal detachments

NCT ID: NCT06289205 Recruiting - Clinical trials for Proliferative Vitreoretinopathy

"Comparing Methotrexate Usage Techniques to Prevent Proliferative Vitreoretinopaty After Retinal Detachment Vitrectomy"

Start date: March 2024
Phase: Phase 1/Phase 2
Study type: Interventional

This clinical trial, involving participants with rhegmatogenous retinal detachment, aims to compare Methotrexate Usage Techniques in preventing Proliferative Vitreoretinopathy (PVR) after vitrectomy. The study will evaluate the development of PVR, retinal detachment recurrence, and improvement in visual acuity. Participants will undergo retinal detachment surgery using the vitrectomy technique and will be divided into two groups. One group will receive Methotrexate infusion during surgery, while the other will receive repeated Methotrexate injections post-surgery. The researcher will analyze and compare outcomes between the two groups.

NCT ID: NCT06194760 Active, not recruiting - Retinal Detachment Clinical Trials

Evaluation of Vitrectomy With ILM Peeling in Myopic Macular Hole With Only Posterior Retinal Detachment

Start date: January 1, 2022
Phase: N/A
Study type: Interventional

Retinal detachment (RD) resulting from the macular hole (MH), also known as MH-induced RD (MHRD), most commonly occurs in eyes with high myopia and results in irreversible visual disorders. Although ILM peeling for MHRD reportedly achieves a high retinal reattachment rate that ranges from 70% to 100%, the MH closure rate is relatively low, ranging from 10% to 70%.

NCT ID: NCT06166914 Completed - Retinal Detachment Clinical Trials

Efficacy of 5-fluorouracil and Low Molecular Weight Heparin in High-risk Pediatric Retinal Detachment

Start date: October 21, 2021
Phase: N/A
Study type: Interventional

EVALUATION OF 5-FLOUROURACIL AND LOW MOLECULAR WEIGHT HEPARIN INTRAOPERATIVE INFUSION IN PREVENTING PROLIFERATIVE VITREORETINOPATHY IN HIGH RISK PEDIATRIC RHEGMATOGENOUS RETINAL DETACHMENT

NCT ID: NCT06056596 Recruiting - Retinal Detachment Clinical Trials

Lamivudine and Plasma Markers of Inflammation in Retinal Detachment

Start date: January 30, 2024
Phase: Early Phase 1
Study type: Interventional

The goal of this clinical trial is to test whether an oral medication (lamivudine) enters the eye and reduces blood markers of inflammation in people who undergo retinal detachment surgery (pars plana vitrectomy). Participants will take the study medication or placebo, and the researchers will measure blood markers of inflammation before and after surgery. The researchers will also measure the amount of medication in the blood and fluid inside the participant's eye (which is collected during surgery).

NCT ID: NCT06033703 Not yet recruiting - Clinical trials for Rhegmatogenous Retinal Detachment

Topical Netarsudil for the Prevention of Proliferative Vitreoretinopathy in Patients With Retinal Detachment

Start date: February 2024
Phase: Phase 1/Phase 2
Study type: Interventional

This study has two main objectives. The first objective is to study the pharmacokinetics of topical netarsudil administration in the posterior segment of the eye, where netarsudil must exert its effect in order to prevent formation of tractional membranes. The second objective is to assess the safety profile of topical netarsudil in the pre- and post-operative periods. A secondary objective of the study is to begin to assess signs of efficacy in preventing formation of tractional membranes post-operatively.

NCT ID: NCT05993208 Completed - Retinal Detachment Clinical Trials

Correlation Between OCT and mFERG Findings With VA After Vitrectomy Surgery for Retinal Detachment

Start date: January 1, 2023
Phase:
Study type: Observational

Correlation between optical coherence tomography and multifocal electroretinogram findings with visual acuity after vitrectomy surgery for Retinal detachment.

NCT ID: NCT05863312 Recruiting - Retinal Detachment Clinical Trials

REtinal Detachment Outcomes Study

REDOS
Start date: September 26, 2023
Phase: N/A
Study type: Interventional

Background: Few large randomized controlled trials provide strong evidence to guide surgical repair of primary rhegmatogenous retinal detachment (RRD) repair. The purpose of this factorial, single-blind, randomized controlled trial is to analyze and compare the surgical outcomes, functional visual outcomes, complications, and quality of life associated with RRD repair using (A) pars plana vitrectomy only (PPV) or PPV with scleral buckle (PPV-SB) and (B) sulfur hexafluoride gas (SF6) or perfluoropropane gas (C3F8) tamponade. Methods: Eligible patients with moderately complex RRD will be randomized 1:1 to PPV or PPV-SB and 1:1 to SF6 or C3F8 gas tamponade. Approximately 560 patients will be recruited to be able to detect a difference of around 10% in SSAS rate between groups. Patients will be followed using multimodal imaging and quality of life questionnaires before and after the surgical repair until 1 year postoperative. The primary outcome will be single surgery anatomic success (SSAS), defined as absence of reoperation for recurrent RRD in the operating room. Secondary outcomes will be pinhole visual acuity (PHVA) at 8-10 weeks and 6 months, final best-corrected visual acuity (BCVA), final retina status (i.e., attached or detached), time to onset of RRD recurrence, severity and number of complications, and questionnaire results. Discussion: This will be the first 2 × 2 factorial randomized controlled trial examining repair techniques in primary RRD. It will also be the first randomized controlled trial to compare gas tamponade between the two most common agents. Notably, it will be adequately powered to detect a clinically significant effect size. The use of multimodal imaging will also be a novel aspect of this study, allowing us to compare head-to-head the impact of adding an SB to the retina's recovery after RRD repair and of differing gas tamponades. Until now, the treatment of RRD has been largely guided by pragmatic retrospective cohort studies. There is a lack of strong evidence guiding therapeutic decisions and this trial will address (1) whether supplemental SB is justified and (2) whether longer duration gas tamponade with C3F8 is necessary.